^
No biomarker
Endometrial Cancer
pembrolizumab + lenvatinib
Sensitive
:
A1
Merck (MSD) Press Release - 4d
MSI-H/dMMR
Endometrial Cancer
dostarlimab
Sensitive
:
A1
AnaptysBio Press Release - 2wk
CCNE1 overexpression
Endometrial Cancer
AZD1775
Sensitive
:
C3
Clin Cancer Res - 3wk
HER-2 expression
Endometrial Adenocarcinoma
trastuzumab
Sensitive
:
A2
NTRK1 fusion
Endometrial Cancer
entrectinib
Sensitive
:
A2
NTRK2 fusion
Endometrial Cancer
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Endometrial Cancer
larotrectinib
Sensitive
:
A2
No biomarker
Endometrial Cancer
cisplatin + paclitaxel + SGN-15
Sensitive
:
A2
NTRK1 fusion
Endometrial Cancer
larotrectinib
Sensitive
:
A2
No biomarker
Endometrial Cancer
carboplatin + docetaxel
Sensitive
:
A2
No biomarker
Endometrial Cancer
docetaxel
Sensitive
:
A2
HER-2 positive
Endometrial Cancer
trastuzumab
Sensitive
:
A2
TMB-H
Endometrial Cancer
pembrolizumab
Sensitive
:
A2
No biomarker
Endometrial Cancer
cisplatin + ifosfamide
Sensitive
:
A2
No biomarker
Endometrial Cancer
paclitaxel + ifosfamide
Sensitive
:
A2
No biomarker
Endometrial Cancer
ifosfamide
Sensitive
:
A2
No biomarker
Endometrial Cancer
topotecan
Sensitive
:
A2
No biomarker
Endometrial Cancer
albumin-bound paclitaxel
Sensitive
:
A2
No biomarker
Endometrial Cancer
paclitaxel
Sensitive
:
A2
No biomarker
Endometrial Cancer
cisplatin + SGN-15
Sensitive
:
A2
No biomarker
Endometrial Cancer
pegylated liposomal doxorubicin
Sensitive
:
A2
No biomarker
Endometrial Cancer
SGN-15
Sensitive
:
A2
No biomarker
Endometrial Cancer
carboplatin
Sensitive
:
A2
No biomarker
Endometrial Cancer
cisplatin
Sensitive
:
A2
No biomarker
Endometrial Cancer
carboplatin + paclitaxel
Sensitive
:
A2
No biomarker
Endometrial Cancer
temsirolimus
Sensitive
:
A2
No biomarker
Endometrial Cancer
bevacizumab
Sensitive
:
A2
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our